<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940805-2-00138</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=3 --> During the March 3&hyph;4, 1994, Recombinant DNA Advisory Committee meeting,  <!-- PJG 0012 frnewline --> Dr. Doris Zallen, Chair of the Working Group on Informed Consent, provided a  <!-- PJG 0012 frnewline --> summary of the proposed amendments to Appendix M&hyph;I&hyph;D, Informed Consent.  <!-- PJG 0012 frnewline --> Two versions of revised Appendix M&hyph;I&hyph;D were presented: (1) the version  <!-- PJG 0012 frnewline --> drafted by the working group, and (2) a modified version incorporating the  <!-- PJG 0012 frnewline --> modifications suggested by Mr. Alex Capron. The Recombinant DNA Advisory  <!-- PJG 0012 frnewline --> Committee recommended that the working group should develop a consolidated  <!-- PJG 0012 frnewline --> version of Appendix M&hyph;I&hyph;D which includes language from both proposed  <!-- PJG 0012 frnewline --> documents. The Recombinant DNA Advisory Committee suggested that  <!-- PJG 0012 frnewline --> questions should be prefaced with an explanation as to the necessity for the  <!-- PJG 0012 frnewline --> requested information.  <!-- PJG 0012 frnewline --> On April 27, 1994, Dr. Zallen submitted revised amendments to Appendix M&hyph;I&hyph;  <!-- PJG 0012 frnewline --> D, Informed Consent, in response to the specific comments posed by the  <!-- PJG 0012 frnewline --> Recombinant DNA Advisory Committee at its March 3&hyph;4, 1994, meeting. The  <!-- PJG 0012 frnewline --> proposed amendments were reviewed by the Recombinant DNA Advisory  <!-- PJG 0012 frnewline --> Committee during the June 9&hyph;10, 1994, meeting. The Recombinant DNA  <!-- PJG 0012 frnewline --> Advisory Committee approved a motion to accept the proposed amendments  <!-- PJG 0012 frnewline --> with minor editorial changes to Appendix M&hyph;I&hyph;D, Informed Consent, by a vote of  <!-- PJG 0012 frnewline --> 13 in favor, 0 opposed, and no abstentions.  <!-- PJG 0012 frnewline --> The amended version of Appendix M&hyph;I&hyph;D, Informed Consent, reads:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=74 g=1 f=3 --> Appendix M&hyph;I&hyph;D. Informed Consent  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> In accordance with the requirements of DHHS regulations for the Protection of  <!-- PJG 0012 frnewline --> Human Subjects (45 CFR Part 46), investigators should indicate how subjects  <!-- PJG 0012 frnewline --> will be informed about the proposed study and the manner in which their  <!-- PJG 0012 frnewline --> consent will be solicited. They should also indicate how the Informed Consent  <!-- PJG 0012 frnewline --> document makes clear the special requirements of gene transfer research.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=73 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;1. Communication About the Study to Potential Participants  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;1&hyph;a. <!-- PJG 0012 frnewline --> Which members of the research group and/or institution  <!-- PJG 0012 frnewline --> will be responsible for contacting potential participants and for describing the  <!-- PJG 0012 frnewline --> study to them? What procedures will be used to avoid possible conflicts of  <!-- PJG 0012 frnewline --> interest if the investigator is also providing medical care to potential subjects?  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;1&hyph;b. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> How will the major points covered in Appendices M&hyph;I&hyph;A  <!-- PJG 0012 frnewline --> through M&hyph;I&hyph;C be disclosed to potential participants and/or their parents or  <!-- PJG 0012 frnewline --> guardians in language that is understandable to them?  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;1&hyph;c. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> What is the length of time that potential participants will  <!-- PJG 0012 frnewline --> have to make a decision about their participation in the study?  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;1&hyph;d. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> If the study involves pediatric or mentally handicapped  <!-- PJG 0012 frnewline --> subjects, how will the assent of each person be obtained?  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=73 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2. Informed Consent Document  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            